Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents

Carter Thomas Davis, MD, Arati V. Rao, MD, Eross Guadalupe, Dale J. Christensen, PhD, J. Brice Weinberg, MD

Blood (2016) 128 (22): 5126.

https://doi.org/10.1182/blood.V128.22.5126.5126

Published: 2016

Journal Articles

OP449, a Novel SET Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In Drug-Resistant Myeloid Leukemias

Anupriya Agarwal, Ryan J. Meckenzie, B.S., Raffaella Pippa, Ph.D., Christopher A. Eide, Jessica Oddo, B.S., Jeffrey W. Tyner, Rosalie Sears, Ph.D., Michael P. Vitek, Ph.D., Maria D. Odero, M.D., Ph.D., Dale J. Christensen, Ph.D., Brian J. Druker

Blood (2013) 122 (21): 2511.

https://doi.org/10.1182/blood.V122.21.2511.2511

Published: 2013

Journal Articles

A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABL T315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,

Anupriya Agarwal, PhD, Ryan MacKenzie, BS, Jessica Oddo, B.S., Michael P Vitek, PhD, Dale J. Christensen, PhD, Brian J. Druker

Blood (2011) 118 (21): 3757.

https://doi.org/10.1182/blood.V118.21.3757.3757

Published: 2011

Journal Articles

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

Dale J. Christensen, Youwei Chen, Jessica Oddo, Karen M. Matta, Jessica Neil, Evan D. Davis, Alicia D. Volkheimer, Mark C. Lanasa, Daphne R. Friedman, Barbara K. Goodman, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Michael P. Vitek, J. Brice Weinberg

Blood (2011) 118 (15): 4150–4158.

https://doi.org/10.1182/blood-2011-04-351072

Published: 2011

Includes: Supplemental data

Journal Articles

Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas

Dale J. Christensen, PhD, Jessica Oddo, B.S., Karen Bond, Alicia Volkheimer, M.S., Youwei Chen, MD, Evan Davis, BS, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos de Castro, III, MD, Joseph O. Moore, MD, Michael P Vitek, PhD, J. Brice Weinberg, MD

Blood (2010) 116 (21): 4190.

https://doi.org/10.1182/blood.V116.21.4190.4190

Published: 2010

Journal Articles

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Dale J. Christensen, PhD, Karen M. Bond, BS, Alicia D. Volkheimer, MS, Jessica Oddo, BS, Youwei Chen, MD, Jon P. Gockerman, MD, Joseph O. Moore, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, Michael P. Vitek, PhD, J. Brice Weinberg, MD

Blood (2009) 114 (22): 802.

https://doi.org/10.1182/blood.V114.22.802.802

Published: 2009

Journal Articles

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Blood (2008) 112 (11): 359.

https://doi.org/10.1182/blood.V112.11.359.359

Published: 2008

NARROW

Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents

OP449, a Novel SET Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In Drug-Resistant Myeloid Leukemias

A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABL T315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Email alerts

ASH Publications

American Society of Hematology

Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents

OP449, a Novel SET Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In Drug-Resistant Myeloid Leukemias

A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABL T315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only